Penumbra, Inc. PEN | NYSE
Next Earnings: Jul 28, 2025
Company Overview:
6.4 Year PEN Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
PEN Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for PEN
Based on past 6.4-year performance, here are PEN growth metrics:
Share price CAGR of +8.98%
Dividend CAGR of +0%
Using PEN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| PEN (DRIP) | PEN - No DRIP | |
|---|---|---|
| Current Price | $252.32 | $252.32 |
| Start Shares | 39.63 | 39.63 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 39.63 | 39.63 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $547.18 | $252.32 |
| Total Dividends | $0 | $0 |
| Final Value | $21,686 | $10,000 |
NOTE: Above numbers are our estimate based on PEN's Dividend and Price CAGR over past 6.4 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Penumbra, Inc. (PEN) had its IPO on 2015-09-18, and is trader on NYSE stock exchange.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
PEN website: https://www.penumbrainc.com
